Sterling Capital Management’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.1K Buy
2,119
+1,788
+540% +$19.8K ﹤0.01% 2145
2026
Q2
$3.41K Sell
331
-40
-11% -$302 ﹤0.01% 2806
2026
Q1
$1.82K Sell
371
-139
-27% -$756 ﹤0.01% 3012
2025
Q4
$2.88K Buy
510
+156
+44% +$839 ﹤0.01% 3015
2025
Q3
$1.8K Buy
354
+192
+119% +$1.11K ﹤0.01% 2996
2025
Q2
$820 Buy
162
+121
+295% +$623 ﹤0.01% 3088
2025
Q1
$232 Buy
41
+21
+105% +$172 ﹤0.01% 3068
2024
Q4
$174 Hold
20
– – ﹤0.01% 3129
2024
Q3
$139 Buy
+20
New +$124 ﹤0.01% 3151

Other funds holding CADL

Sterling Capital Management's CADL Position: Q3 2026 in Review

Sterling Capital Management increased its Candel Therapeutics (CADL) stake by 540% in Q3 2026, buying an estimated $19.8K and bringing the position to 2,119 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2145.

Sterling Capital Management first reported a position in CADL in Q3 2024 and has held it in 9 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Sterling Capital Management held 2,119 shares of Candel Therapeutics worth $22.1K as of Q3 2026.
  • Sterling Capital Management bought 1,788 Candel Therapeutics shares in Q3 2026, an estimated $19.8K.
  • Candel Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2145 holding.
  • Sterling Capital Management first reported a position in Candel Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.